Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Berotralstat Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioCryst's NDA for ORLADEYO Oral Granules in HAE Kids Accepted by FDA
Details : Orladeyo (berotralstat), plasma kallikrein inhbitor, which is being evaluated for the treatment in pediatric patients with hereditary angioedema aged 2 to <11 years.
Product Name : Orladeyo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 14, 2025
Lead Product(s) : Berotralstat Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable